SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): November 17, 2017
Sage Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
215 First Street
|(Address of principal executive offices)||(Zip Code)|
Registrants telephone number, including area code (617) 299-8380
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|☐||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|☐||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|☐||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|☐||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|Item 8.01||Other Events.|
On November 17, 2017, Sage Therapeutics, Inc. (the Company) completed the sale of 4,058,822 shares of its common stock to the underwriters as part of the Companys previously announced public offering at the public offering price of $85.00 per share, less underwriting discounts and commissions, including the exercise in full by the underwriters of their option to purchase up to 529,411 additional shares of common stock of the Company (the Offering). The Companys proceeds raised in the offering, after underwriting discounts and commissions, and before estimated expenses of the offering, were approximately $326.0 million.
On November 17, 2017, the Company issued a press release announcing the completion of the Offering. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
|Item 9.01||Financial Statements and Exhibits.|
|99.1||Press release issued by Sage Therapeutics, Inc. on November 17, 2017.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: November 17, 2017||SAGE THERAPEUTICS, INC.|
Anne Marie Cook
Senior Vice President, General Counsel
Sage Therapeutics Announces Closing of $345 Million Public Offering of Common
Stock, Including Full Exercise of Option to Purchase Additional Shares
CAMBRIDGE, Mass., November 17, 2017 Sage Therapeutics (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 529,411 shares at the public offering price of $85.00 per share. The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by Sage to 4,058,822 shares and increased the amount of gross proceeds raised in the offering, before underwriting discounts and estimated expenses of the offering, to approximately $345 million.
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Morgan Stanley acted as joint book-running managers for the offering. Cowen and Company, LLC and Leerink Partners LLC served as lead managers.
The shares were being offered by Sage pursuant to an automatically effective shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (SEC). The final prospectus supplement relating to and describing the terms of the offering was filed with the SEC on November 15, 2017, and is available on the SECs web site at www.sec.gov.
Copies of the final prospectus supplement and the accompanying prospectus relating to these securities may also be obtained by contacting one of the following: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by telephone at 866-803-9204; Goldman Sachs & Co. LLC at Prospectus Department, 200 West Street, New York, New York 10282, by telephone at 866-471-2526, by facsimile at 212-902-9316 or by e-mail at email@example.com; or Morgan Stanley & Co. LLC at Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sages lead program, a proprietary IV formulation of brexanolone (SAGE-547), has completed two Phase 3 clinical trials in postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders.
Various statements in this release concerning Sages future expectations, plans and prospects, including without limitation, Sages plans to develop products to treat CNS disorders, constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond Sages control, which could cause actual results to differ materially from those indicated by these forward-looking statements, including, without limitation: the potential that Sages completed, ongoing and future clinical and non-clinical data may not be sufficient to file for or gain regulatory approval to launch and commercialize its product candidates; the potential that future pre-clinical and clinical results may be negative or may not support further development of Sages product candidates or that Sage may not be able to successfully demonstrate the efficacy and safety of its product candidates at each stage of development in a manner sufficient to obtain approval; the risk that actions or decisions of regulatory agencies may affect the initiation, timing and progress of clinical trials or Sages ability to file for or obtain approval; the potential for unexpected adverse events in the conduct of one of Sages clinical trials to impact its ability to continue the clinical trial or further development of a product candidate; the risk that Sage may encounter other unexpected hurdles or issues in the development and manufacture of its product candidates that may impact its timing or progress, as well as those risks more fully discussed in the section entitled Risk Factors in Sages most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Sages subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Sages views only as of today and should not be relied upon as representing its views as of any subsequent date. Sage explicitly disclaims any obligation to update any forward-looking statements.
|Investor Contact:||Media Contact:|
Paul Cox, 617-299-8377
Suda Communications LLC
Maureen L. Suda, 585-355-1134